# Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2019

- Company: [Amneal Pharmaceuticals, Inc.](/companies/amrx.md) (CIK 1723128)
- Form: 10-Q
- Filed: 2019-11-07
- Accepted by EDGAR: Nov 6, 2019, 20:09 ET
- Period: 2019-09-30
- Accession: 0001564590-19-041240
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1723128/000156459019041240/amrx-10q_20190930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1723128/000156459019041240/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $378.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $1.23bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $267.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $873.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $54.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | $242.8m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-07-01 to 2019-09-30 | $38.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2019-01-01 to 2019-09-30 | $140.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2019-07-01 to 2019-09-30 | $63.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2019-01-01 to 2019-09-30 | $215.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | −$112.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | −$225.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | $389.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-30 | $375.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | −$265.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | −$329.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | −$2.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-30 | −$2.56 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-07-01 to 2019-09-30 | −$2.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2019-01-01 to 2019-09-30 | −$2.56 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-07-01 to 2019-09-30 | 130,729,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2019-01-01 to 2019-09-30 | 128,822,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | $52.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-01-01 to 2019-09-30 | $42.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2019-01-01 to 2019-09-30 | $0 | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2019-09-30 | $212.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $1.21bn | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $3.70bn | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $534.9m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2019-09-30 | $2.61bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2019-09-30 | $218.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 54,398 characters.

Amneal Pharmaceuticals, Inc. (the "Company," "we," "us," or "our") is a pharmaceutical company specializing in developing, manufacturing, marketing and distributing high-value generic pharmaceutical products across a broad array of dosage forms and therapeutic areas, as well as branded products. We were formed on October 4, 2017, under the name Atlas Holdings, Inc. for the purpose of facilitating the combination (the "Combination") of Impax Laboratories, Inc. ("Impax") and Amneal Pharmaceuticals LLC ("Amneal"), which closed on May 4, 2018.

The following discussion and analysis for the three and nine months ended September 30, 2019 should be read in conjunction with the consolidated financial statements and related notes of thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, 2018 included in our 2018 Annual Report on Form 10-K.

Our Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system ("CNS") disorders, including migraine and Parkinson’s disease. Our portfolio of products includes Rytary®, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. In addition to Rytary®, our promoted Specialty portfolio includes Zomig® (zolmitriptan) products, for the treatment of migraine headaches, which is sold under a license agreement with AstraZeneca UK Limited, Emverm® (mebendazole) 100 mg chewable tablets, for the treatment of pinworm, whipworm, common roundworm, common hookworm and American hookworm in single or mixed infections, and Unithroid® (levothyroxine sodium), for the treatment of hypothyroidism, which is sold under a license and distribution agreement with JSP.

For Specialty products, the majority of the product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S. and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales.

The Company’s Generics segment includes over 200 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics (which are sterile pharmaceutical preparations administered for ocular conditions), films, transdermal patches and topicals (which are creams or gels designed to administer pharmaceuticals locally through the skin). We focus on developing products with substantial barriers-to-entry resulting from complex drug formulations or manufacturing, or legal or regulatory challenges. Generic products, particularly in the U.S., generally contribute most significantly to revenues and gross margins at the time of their launch, and even more so in periods of market exclusivity, or in periods of limited generic competition. As such, the timing of new product introductions can have a significant impact on the Company’s financial results. The entrance into the market of additional competition generally has a negative impact on the volume and pricing of the affected products. Additionally, pricing is often affected by factors outside of the Company’s control.

The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our *2018 Annual Report on Form 10-K.*

In 2019, our Generics segment has experienced both industry-wide and company-specific challenges that resulted in our financial performance falling short of our expectations since the beginning of the year. Such challenges include increased competition on certain key generic products, the uncertainty of supply of epinephrine auto-injector (generic Adrenaclick®) from our third-party supplier, and delays in key product approvals and launches, including generic NuvaRing®. We expect these challenges and others to persist at least for the remainder of 2019.

To address these challenges, we have, among other things, conducted an in depth, company wide review of our organizational structures, operational budgets, current and future capital projects and existing capability and infrastructure alignments, resulting in the comprehensive restructuring plan we announced in July 2019. The revised restructuring plan is designed to reduce costs, optimize our organizational and manufacturing infrastructure, which we expect to reduce costs by approximately $40 million per year once the plan has been executed. For additional information, refer to *Note 6, Restructuring and Other Charges*, to the unaudited financial statements in Part I, Item 1 of this report.

Our current year results continue to be impacted by our Combination with Impax as a result of our continued actions to adjust our operations and cost structure. The historical financial results of the Company for the periods prior the May 4, 2018 closing of the Combination are the historical financial results of Amneal, and thus the current period results, and balances, may not be comparable to prior years as the current year includes the results of Impax from May 4, 2018.

### Results of Operations

### Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the three and nine months ended September 30, 2019 and 2018 (in thousands):

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $378,283 | $476,487 | $1,229,045 | $1,165,463 |
| Cost of goods sold | 267,717 | 268,567 | 873,841 | 634,653 |
| Cost of goods sold impairment charges | 56,132 | 7,815 | 112,441 | 7,815 |
| **Gross profit** | 54,434 | 200,105 | 242,763 | 522,995 |
| Selling, general and administrative | 63,797 | 75,486 | 215,514 | 156,610 |
| Research and development | 38,125 | 42,349 | 139,999 | 136,893 |
| In-process research and development impairment charges | 23,382 | 650 | 46,169 | 650 |
| Charges (gains) related to legal matters, net | 14,750 | 2,589 | 14,750 | (411) |
| Intellectual property legal development expenses | 2,586 | 4,401 | 9,263 | 13,024 |
| Acquisition, transaction-related and integration expenses | 3,131 | 2,231 | 12,682 | 216,873 |
| Restructuring and other charges | 20,937 | (2,156) | 29,933 | 42,309 |
| **Operating (loss) income** | (112,274) | 74,555 | (225,547) | (42,953) |
| Gain from reduction of tax receivable agreement liability | 192,844 | — | 192,844 | — |
| Other expense, net | (54,294) | (51,981) | (130,428) | (144,963) |
| Total other income (expense), net | 138,550 | (51,981) | 62,416 | (144,963) |
| Income (loss) before income taxes | 26,276 | 22,574 | (163,131) | (187,916) |
| Provision for (benefit from) income taxes | 389,668 | 5,109 | 375,539 | (6,943) |
| **Net (loss) income** | $(363,392) | $17,465 | $(538,670) | $(180,973) |

#### Net Revenue

Net revenue for the three months ended September 30, 2019 decreased by 21%, or $98 million, to $378 million compared to $476 million for the three months ended September 30, 2018. The decrease is primarily attributable to price and volume erosion of $132 million mainly in our Generics segment, $12 million in divestitures of our international businesses and $15 million in the loss of exclusivity on Albenza in our Specialty segment which were partially offset by a $40 million contribution from Levothyroxine sodium tablets ("Levothyroxine") which launched in the fourth quarter 2018, and $19 million from new product launches in our Generics segment.

Net revenue for the nine months ended September 30, 2019 increased by 5%, or $64 million, to $1,229 million compared to $1,165 million for the nine months ended September 30, 2018. The increase over the prior year period is primarily attributable to a $211 million timing impact from the Combination and the acquisition of Gemini, a $135 million contribution from Levothyroxine, and $36 million from new product launches in our Generics segment which were partially offset by price and volume erosion of $240 million mainly in our Generics segment, $38 million from the loss of exclusivity on Albenza in our Specialty segment and $27 million from the divestitures of our international businesses in the UK and Germany.

#### Cost of Goods Sold and Gross Profit

Cost of goods sold, including impairment charges, increased 17%, or $47 million, to $324 million for the three months ended September 30, 2019 as compared to $276 million for the three months ended September 30, 2018. The increase in cost of goods sold was primarily attributable to $48 million of impairment charges on intangible assets primarily in our Generics segment, $14 million in inventory charges, and $13 million in amortization of intangible assets, partially offset by a year over year decline in Generics volume.

Accordingly, gross profit for the three months ended September 30, 2019 was $54 million (14% of total revenues) as compared to gross profit of $200 million (42% of total revenues) for the three months ended September 30, 2018. Our gross profit as a percentage of sales declined compared to the prior year period primarily as a result of the impairment charges as well as price and volume erosion in the Generics segment.

Cost of goods sold, including impairment charges, increased 54%, or $344 million, to $986 million for the nine months ended September 30, 2019 as compared to $642 million for the nine months ended September 30, 2018. The increase in cost of goods sold was primarily attributable to higher product sales due to the Combination and Gemini acquisition, $105 million in intangible impairment mainly in our Generics segment, incremental expenses related to the Combination and the acquisition of Gemini, including amortization of intangible assets of $61 million and royalties of $22 million, $47 million of inventory charges in our Generics segment and $36 million of expenses related to the Levothyroxine transition agreement with Lannett Company ("Lannett").

Accordingly, gross profit for the nine months ended September 30, 2019 was $243 million (20% of total revenues) as compared to gross profit of $523 million (45% of total revenues) for the nine months ended September 30, 2018. Our gross profit as a percentage of sales declined compared to the prior year period primarily as a result of the impairment charges, increased inventory related charges, and price erosion in our Generics segment as well as other factors described above.

#### Selling, General, and Administrative

Selling, general, and administrative ("SG&A") expenses for the three months ended September 30, 2019 were $64 million, as compared to $75 million for the three months ended September 30, 2018. The $11 million decrease from the prior year period was primarily due to post Combination synergies.

SG&A expenses for the nine months ended September 30, 2019 were $216 million, as compared to $157 million for the nine months ended September 30, 2018. The $59 million increase from the prior year was primarily due to the timing of the Combination and Gemini acquisition, including selling expenses associated with our Specialty segment, stock-based compensation and higher Corporate functions spend including public company costs that did not exist prior to the Combination. These increases were partially offset by post Combination synergies.

#### Research and Development

Research and development expenses for the three months ended September 30, 2019 were $38 million as compared to $42 million for the three months ended September 30, 2018. The $4 million decrease is primarily attributable to post Combination synergies.

Research and development expenses for the nine months ended September 30, 2019 were $140 million, as compared to $137 million for the nine months ended September 30, 2018. The $3 million increase compared to the prior year is primarily attributable to the timing of the Combination and increased milestone payments in our Generics segment partially offset by post Combination synergies.

#### In-Process Research and Development Impairment Charges

For the three months ended September 30, 2019, we recognized in-process research and development (“IPR&D”) impairment charges of $23 million associated with four intangible assets that were acquired as part of the Combination. The impairment charges were the result of expected significant price erosion for the products resulting in significantly lower than expected future cash flows. IPR&D impairment charges for the three months ended September 30, 2018 were less than $1 million.

We recognized IPR&D impairment charges of $46 million for the nine months ended September 30, 2019. The charges are primarily associated with six products in our Generics segment that were acquired as part of the Combination. The impairment charges were the result of expected significant price erosion for the products resulting in significantly lower than expected future cash flows. IPR&D impairment charges for nine months ended September 30, 2018 were less than $1 million.

#### Intellectual Property Legal Development Expense

Intellectual property legal development expenses for the three months ended September 30, 2019 were $3 million as compared to $4 million for the three months ended September 30, 2018. Intellectual property legal development expenses for the nine months ended September 30, 2019 were $9 million as compared to $13 million for the nine months ended September 30, 2018. These costs include, but are not limited to, formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend the intellectual property.

#### Charges (Gains) Related to Legal Matters, Net

For the three and nine months ended September 30, 2019, the Company recorded a net charge of $15 million primarily associated with an agreement in principle with Teva Pharmaceuticals. For further details, see *Note 13. Commitments and Contingencies.*

#### Acquisition, Transaction-Related and Integration Expenses

We recognized approximately $3 million of acquisition, transaction-related and integration expenses for the three months ended September 30, 2019 as compared to $2 million for the three months ended September 30, 2018. We recognized approximately $13 million of acquisition, transaction-related and integration expenses for the nine months ended September 30, 2019 as compared to $217 million for the nine months ended September 30, 2018.

Expenses for the three and nine months ended September 30, 2019 were related to the ongoing integration and site closure expenses associated with Impax and Gemini. During the prior year period, expenses were primarily for transaction-related costs associated with pre and post Combination activities.

#### Restructuring and Other Charges

On July 10, 2019, the Company announced a plan to restructure its operations that is intended to reduce costs and optimize its organizational and manufacturing infrastructure. Pursuant to the restructuring plan as revised, the Company expects to reduce its headcount by approximately 300 to 350, primarily by closing its manufacturing facility located in Hauppauge, NY. As a result of the restructuring plan, the Company estimates that it will incur a pre-tax restructuring charge of approximately $6 to $8 million of cash expenditures related to severance benefits.

We recorded $21 million of restructuring and other charges for the three months ended September 30, 2019, which primarily consisted of $11 million of property plant and equipment and right of use asset impairment charges in connection with the planned closure of the Company’s Hauppauge, NY facility. Restructuring and other charges also consisted of employee restructuring separation charges of approximately $6 million for severance provided pursuant to our severance programs for employees at our Hauppauge, NY, Hayward, CA and other facilities and approximately $4 million of other employee severance charges. The restructuring and other charges for the three months ended September 30, 2018 were a benefit of $2 million, which was primarily related to changes in estimates for certain employee-related separation liabilities associated with employees who exited early.

We recorded $30 million of restructuring and other charges for the nine months ended September 30, 2019, which primarily consisted of $11 million of property plant and equipment and right of use asset impairment charges in connection with the planned closure of the Company’s Hauppauge, NY facility. Restructuring and other charges also consisted of employee restructuring separation charges of approximately $9 million for severance provided pursuant to our severance programs for employees at our Hauppauge, NY, Hayward, CA and other facilities and $9 million of other employee severance charges. The restructuring and other charges for the nine months ended September 30, 2018 were $42 million, which were primarily associated with a reduction in workforce resulting from the Combination.

#### Gain From Reduction in Tax Receivable Agreement Liability

In connection with the Combination, the Company entered into a tax receivable agreement (“TRA”) for which it is generally required to pay the other holders of Amneal Common Units 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it is deemed to realize as a result of certain tax attributes of their Amneal Common Units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal Common Units for shares of Class A Common Stock and (ii) tax benefits attributable to payments made under the TRA (including imputed interest).

During the three months and nine months ended September 30, 2019, we recorded a $372 million valuation allowance to reduce our deferred tax assets (“DTAs”). For further discussion, see Provision For (Benefit From) Income Taxes below. In conjunction with the valuation allowance of our DTAs, we reversed the accrued TRA liability, which resulted in a $193 million gain to our statement of operations.

#### Other Expense, Net

Other expense, net was $54 million for the quarter ended September 30, 2019, as compared to $52 million for the quarter ended September 30, 2018. The increase of $2 million was primarily attributable to $7 million of additional expense from the change in foreign exchange rates, primarily as a result of the impact of fluctuations in the Swiss Franc, Indian Rupee and Euro on intercompany loans, partially offset by $3 million decline in loss on the sale of international businesses and a $1 million savings on interest expense.

Other expense, net was $130 million for the nine months ended September 30, 2019, as compared to $145 million for the nine months ended September 30, 2018. The decrease of $15 million was primarily attributable to a $20 million decline in loss from extinguishment of debt, a $13 million benefit from the change in foreign exchange rates, primarily as a result of the impact of fluctuations in the Swiss Franc, Indian Rupee and Euro on intercompany loans and a $10 million beneficial impact from the divestitures of our international businesses. These decreases were partially offset by $29 million of additional interest expense associated with an increase in long-term debt related to the Combination and the acquisition of Gemini.

#### Provision For (Benefit From) Income Taxes

The provision for income taxes was $390 million for the three months ended September 30, 2019 as compared to the provision for income taxes of $5 million for the three months ended September 30, 2018. The provision for income taxes was $376 million for the nine months ended September 30, 2019, as compared to the benefit from income taxes of $7 million for the nine months ended September 30, 2018.

The change in income tax provision for the three and nine months ended September 30, 2019 is primarily impacted by a $372 million valuation allowance against our DTAs. We recorded valuation allowances against our various DTAs on a jurisdictional basis after it was determined that it is more likely than not that our deferred tax assets will not be realized. The provision for the nine months ended September 30, 2019 compared to the prior year period was also impacted by the company structure. Prior to the Combination, as a limited liability company, income taxes were only provided for the international subsidiaries as all domestic taxes flowed to the members. Subsequent to May 4, 2018, domestic income taxes were also provided for our allocable share of income or losses from Amneal at the prevailing U.S. federal, state, and local corporate income tax rates.

#### Net (Loss) Income

We recognized a net loss for the three months ended September 30, 2019 of $363 million as compared to net income of $17 million for the three months ended September 30, 2018. For the three months ended September 30, 2019, we recorded a $98 million decline in net revenues from the prior year period, a tax provision of $390 million, impairment charges of $79 million on intangible assets, $21 million in restructuring and other charges and $15 million in charges for legal matters, which were partially offset by $193 million from the gain in reduction of TRA liability.

We recognized a net loss for the nine months ended September 30, 2019 of $539 million as compared to net loss of $181 million for the nine months ended September 30, 2018. The year over year increase of $358 million is primarily attributable to a $382 million unfavorable impact from income tax expense, a $150 million of intangible asset impairment charges, a $15 million unfavorable impact on legal matters and incremental expenses related to the Combination and acquisition of Gemini. These increases were partially offset by a $204 million decline in acquisition, transaction related and integration expenses associated with the Combination and Gemini acquisition, a $20 million decline in loss on extinguishment of debt, a $13 million benefit from the change in foreign exchange rates, primarily as a result of the impact of fluctuations in the Swiss Franc, Indian Rupee and Euro on intercompany loans and a $12 million decline in restructuring and other charges.

### Generics

The following table sets forth results of operations for our Generics segment for the three and nine months ended September 30, 2019 and 2018 (in thousands):

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $291,021 | $391,175 | $1,008,562 | $1,028,134 |
| Cost of goods sold | 217,773 | 230,051 | 760,074 | 572,179 |
| Cost of goods sold impairment charges | 49,115 | 7,815 | 105,424 | 7,815 |
| **Gross profit** | 24,133 | 153,309 | 143,064 | 448,140 |
| Selling, general and administrative | 14,256 | 21,030 | 52,783 | 51,854 |
| Research and development | 34,316 | 38,347 | 129,915 | 129,762 |
| In-process research and development impairment charges | 23,382 | 650 | 46,169 | 650 |
| Charges (gains) related to legal matters, net | 14,750 | — | 14,750 | (3,000) |
| Intellectual property legal development expenses | 2,586 | 3,929 | 8,218 | 12,509 |
| Other operating expense (income) | 15,204 | (2,885) | 21,287 | 136,534 |
| **Operating (loss) income** | $(80,361) | $92,238 | $(130,058) | $119,831 |

#### Net Revenue

Generics net revenue was $291 million for the three months ended September 30, 2019, a decrease of $100 million or 26% when compared with the same period in 2018. Volume and pricing erosion of $132 million in our existing business as well as a $17 million decline from the reclassification of Oxymorphone to the Specialty segment (where it is sold as a non-promoted product), and a $12 million decline in international revenues from divestitures were partially offset by $40 million in sales of Levothyroxine which launched in the fourth quarter 2018 and $19 million from new product launches. Favorable volume growth increased revenue in Levothyroxine, Abiraterone Acetate, Chlorpromazine HCI, Guanfacine and Hydroxyprogesterone Caproate Injection, which was partially offset by price and volume declines in revenue of Yuvafem, Diclofenac Gel and Aspirin Dipyridamole ER Capsules.

Generics net revenue was $1,009 million for the nine months ended September 30, 2019, a decrease of $20 million or 2% when compared with the same period in 2018. The year over year decrease was primarily driven by price and volume declines of $249 million in our existing business primarily in Yuvafem, Aspirin Dipyridamole ER Capsules, Diclofenac Gel (price only) and Oseltamavir, a $27 million decline in international revenues from divestitures and $17 million from the reclassification of Oxymorphone, partially offset by $135 million in sales of Levothyroxine, a $113 million impact from the timing of the Combination, and $36 million from new product launches.

#### Cost of Goods Sold and Gross Profit

Generics cost of goods sold, including impairment charges, for the three months ended September 30, 2019 was $267 million, an increase of 12% or $29 million compared to the three months ended September 30, 2018. The year over year increase is primarily associated with $41 million of impairment charges, $14 million in inventory charges, amortization of intangible assets of $5 million and $5 million of royalties partially offset by a $16 million decline of purchase accounting adjustments, a $7 million decline in acquisition and site closure expenses and a year over year decline in volume. The impairment charges are associated with four products that experienced significant price erosion during the three months ended September 2019, without an offsetting increase in customer demand, resulting in significantly lower than expected future cash flows.

Generics gross profit for the three months ended September 30, 2019 was $24 million (8% of total revenues) as compared to gross profit of $153 million (39% of total revenues) for the three months ended September 30, 2018. Our Generics gross profit as a percentage of sales declined compared to the prior year period primarily as a result of $41 million of incremental impairment charges and price erosion in addition to the other factors noted above.

Generics cost of goods sold, including impairment charges, for the nine months ended September 30, 2019 was $865 million, an increase of 49% or $286 million compared to the nine months ended September 30, 2018. The year over year increase is primarily associated with sales of Impax products added to portfolio with the Combination, $98 million in impairment charges primarily associated with six marketed products acquired as part of the Combination and $47 million in inventory charges. The impairment charges are associated with six products that experienced significant price erosion during 2019, without an offsetting increase in customer demand, resulting in significantly lower than expected future cash flows. Cost of goods sold was also unfavorably impacted by $36 million of expenses related to the Levothyroxine transition agreement with Lannett and incremental expenses related to the Combination, including amortization of intangible assets of $22 million, royalties of $17 million and site closure costs of $5 million. These increases were partially offset by a $29 million decrease in purchase accounting adjustments.

Generics gross profit for the nine months ended September 30, 2019 was $143 million (14% of total revenue) as compared to gross profit of $448 million (44% of total revenue) for the nine months ended September 30, 2018. Our Generics gross profit as a percentage of sales declined compared to the prior year period primarily as a result of the $98 million of incremental impairment charges, price erosion and other factors described above.

#### Selling, General, and Administrative

Generics SG&A expenses for the three months ended September 30, 2019 were $14 million, as compared to $21 million for the three months ended September 30, 2018. The $7 million decrease from the prior year period was primarily due to post Combination synergies and the divesting of our UK and Germany businesses.

Generics SG&A expense for the nine months ended September 30, 2019 were $53 million, as compared to $52 million for the nine months ended September 30, 2018. The impact from the timing of the Combination was offset by post Combination synergies and the divesting of our UK and Germany businesses.

#### Research and Development

Generics research and development expenses for the three months ended September 30, 2019 were $34 million as compared to $38 million for the three months ended September 30, 2018. The year over year decrease is primarily attributable to post Combination synergies.

Generics research and development expenses remained consistent for the nine months ended September 30, 2019 and 2018 at $130 million. The impact from the timing of the Combination was offset by post Combination synergies.

#### In-Process Research and Development Impairment Charges

For the three months ended September 30, 2019, we recognized IPR&D impairment charges of $23 million associated with four intangible assets that were partially impaired and one intangible asset that was fully impaired.

For the nine months ended September 30, 2019, we recognized IPR&D impairment charges of $46 million in the Generics segment. The impairment charges are primarily related to six products, all acquired as part of the Combination. For one IPR&D product, the impairment charge was the result of increased competition at launch resulting in significantly lower than expected future cash flows. For one IPR&D product, the impairment charge was the result of a strategic decision to no longer pursue approval of the product. For the other four IPR&D products, the impairment charges were the result of expected significant price erosion for the products resulting in significantly lower than expected future cash flows.

The IPR&D charges for the three and nine months ended September 30, 2018 were less than $1 million.

#### Charges (Gains) Related to Legal Matters, Net

For the three and nine months ended September 30, 2019, the Company recorded a net charge of $15 million primarily associated with an agreement in principle with Teva Pharmaceuticals. For further details, see *Note 13. Commitments and Contingencies.*

Gains for legal matters of $3 million for the nine months ended September 30, 2018 were primarily related to settlements with several innovators of branded pharmaceutical products (none for the three months ended September 30, 2018).

#### Intellectual Property Legal Development Expenses

Generics intellectual property legal development expenses for the three months ended September 30, 2019 were $3 million as compared to $4 million for the prior year period. Generics intellectual property legal development expenses for the nine months ended September 30, 2019 were $8 million as compared to $13 million for the prior year period. For both the three and nine month periods, these costs include, but are not limited to, formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend the intellectual property.

#### Other Operating Expenses (Income)

For the three and nine months ended September 30, 2019, we recorded other expenses of $15 million and $21 million, respectively. These charges were primarily attributable to restructuring, severance, and integration expenses associated with the Combination.

For the three and nine months ended September 30, 2018, we recorded $3 million of other operating income and $137 million of other operating expenses, respectively. For the three months ended September 30, 2018, the $3 million of other operating income was a result of changes in estimates on restructuring charges. For the nine months ended September 30, 2018, the charges were primarily attributable to acquisition, integration and restructuring expenses associated with the Combination.

### Specialty

The following table sets forth results of operations for our Specialty segment for the three and nine months ended September 30, 2019 and 2018 (in thousands):

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $87,262 | $85,312 | $220,483 | $137,329 |
| Cost of goods sold | 49,944 | 38,516 | 113,767 | 62,474 |
| Cost of goods sold impairment charges | 7,017 | — | 7,017 | — |
| **Gross profit** | 30,301 | 46,796 | 99,699 | 74,855 |
| Selling, general and administrative | 20,228 | 19,716 | 57,705 | 33,265 |
| Research and development | 3,809 | 4,002 | 10,084 | 7,131 |
| Intellectual property legal development expenses | — | 472 | 1,045 | 515 |
| Other operating expense (income) | 2,668 | (27) | 6,096 | 2,394 |
| **Operating income** | $3,596 | $22,633 | $24,769 | $31,550 |

Our Specialty segment is comprised of the Impax Specialty business acquired on May 4, 2018 and the Gemini business acquired on May 7, 2018. Prior to these two transactions, we did not have a Specialty segment. Refer to *Note 3. Acquisitions and Divestitures* in our 2018 Annual Report on Form 10-K and in this Quarterly Report on Form 10-Q for further information related to these two transactions.

#### Net Revenue

Specialty net revenue for the three months ended September 30, 2019 was $87 million, an increase of 2% or $2 million compared to the three months ended September 30, 2018. The increase from the prior year period was primarily due to $17 million from the reclassification of Oxymorphone from the Generics segment to the Specialty segment (where it is sold as a non-promoted product), which was partially offset by a $15 million decline in our existing business primarily associated with the loss of exclusivity on Albenza.

Specialty net revenue for the nine months ended September 30, 2019 was $220 million, an increase of 61% or $83 million compared to the nine months ended September 30, 2018. The increase from the prior year period was primarily due to a $99 million timing impact from the Combination and Gemini acquisition, and $17 million from the reclassification of Oxymorphone, which was partially offset by a $29 million decline in our existing business primarily associated with the loss of exclusivity on Albenza.

#### Cost of Goods Sold and Gross Profit

Specialty cost of goods sold, including impairment charges, for the three months ended September 30, 2019 was $57 million, an increase of 48% or $19 million compared to the three months ended September 30, 2018. The increase from the prior year period was primarily due to $8 million of amortization expense and $7 million of impairment charges associated with one marketed product.

Accordingly, Specialty gross profit for the three months ended September 30, 2019 was $30 million (35% of total revenues) as compared to gross profit of $47 million (55% of total revenues) for the three months ended September 30, 2018.

Specialty cost of goods sold, including impairment charges, for the nine months ended September 30, 2019 was $121 million, an increase of $58 million or 93% compared to the nine months ended September 30, 2018. The increase from the prior year period was primarily due to $37 million of amortization expense, increased volume associated with the timing of the Combination and Gemini acquisition and $7 million of impairment charges associated with one marketed product.

Accordingly, Specialty gross profit for the nine months ended September 30, 2019 was $100 million (45% of total revenue) as compared to gross profit of $75 million (55% of total revenues) for the nine months ended September 30, 2018.

#### Selling, General, and Administrative

Specialty SG&A expenses remained consistent for the three months ended September 30, 2019 at $20 million compared to the prior year period.

Specialty SG&A expense for the nine months ended September 30, 2019 was $58 million, as compared to $33 million for the nine months ended September 30, 2018. The $25 million increase from the prior period was primarily due to the timing of the Combination partially offset by post-Combination operating synergies.

#### Research and Development

Specialty research and development expenses remained consistent for the three month period ended September 30, 2019 at $4 million when compared to the prior year period of $4 million.

Specialty research and development expenses for the nine months ended September 30, 2019 were $10 million, as compared to $7 million for the nine months ended September 30, 2018. The $3 million increase from the prior year period was primarily due to clinical costs associated with our bio studies.

#### Other Operating Expenses

For the three months ended September 30, 2019, we recognized other operating expenses of $3 million in the Specialty segment compared to none for the three months ended September 30, 2018. For the nine months ended September 30, 2019, we recognized other operating expenses of $6 million in the Specialty segment compared to $2 million for the nine months ended September 30, 2018. For the three and nine month periods, these expenses were primarily attributable to acquisition, site closure and integration expenses associated with the Combination.

### Liquidity and Capital Resources

Our primary source of liquidity is cash generated from operations, available cash and borrowings under debt financing arrangements, including $433 million of available additional capacity on our asset backed revolving credit facility ("ABL"). We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations and provide sufficient liquidity over the next 12 months. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions and demand for our products, which are factors that may be out of our control.

Our primary uses of capital resources are to fund operating activities, including research and development expenses associated with new product filings, and pharmaceutical product manufacturing expenses, license payments, and spending on production facility expansions and capital equipment items.

Over the next 12 months, we will make substantial payments for monthly interest and quarterly principal amounts due on our term loan under our senior secured credit facility (the "Term Loan"), any future borrowings under the ABL, severance and capital expenditures. We made a $50 million payment to JSP on April 22, 2019 pursuant to the terms of a license and supply agreement, as described in *Note 5. Alliance and Collaboration*. Given the magnitude of projected expenditures, we may require additional funds from our ABL to meet these increased cash needs in the next year.

We are party to a tax receivable agreement that requires us to make cash payments to APHC Holdings LLC (formerly known as Amneal Holdings LLC) ("Holdings") in respect of certain tax benefits that we may realize or may be deemed to realize as a result of redemptions or exchanges of Amneal common units by Holdings. The tax receivable agreement also requires that we make an accelerated payment to Holdings equal to the present value of all future payments due under the agreement upon certain change of control and similar transactions. The timing of any payments under the tax receivable agreement will vary depending upon a number of factors, but payments could be substantial, and could be in excess of the tax savings that we ultimately realize. Because of the foregoing, our obligations under the tax receivable agreement could have a substantial negative impact on our liquidity. For further details, see *Item 1A. Risk Factors* and *Note 8. Income Taxes* in our 2018 Annual Report on Form 10-K.

In addition, pursuant to the limited liability operating agreement of Amneal, in connection with any tax period, Amneal will be required to make distributions to its members, on a pro rata basis in proportion to the number of Amneal Common Units held by each member, of cash until each member (other than the Company) has received an amount at least equal to its assumed tax liability and the Company has received an amount sufficient to enable it to timely satisfy all of its U.S. federal, state and local and non-U.S. tax liabilities, and meet its obligations pursuant to the tax receivable agreement. For the nine months ended September 30, 2019, Amneal made an aggregate of $13 million in tax distributions to Holdings (none for the three months ended September 30, 2019). The amount due to Holdings as of September 30, 2019 is immaterial.

At September 30, 2019, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the United States. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the United States may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.

### Cash Flows

#### (in thousands)

| Cash provided by (used in): | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Operating activities | $52,594 | $(9,421) |
| Investing activities | (14,813) | (401,699) |
| Financing activities | (38,535) | 506,595 |
| Effect of exchange rate changes on cash | (967) | (1,204) |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | $(1,721) | $94,271 |

#### Cash Flows from Operating Activities

Net cash provided by operating activities was $53 million for the nine months ended September 30, 2019 compared to net cash used in operating activities of $9 million for the nine months ended September 30, 2018. The change was primarily attributed to favorable timing of collections of trade accounts receivable and decreased transaction and integration costs partially offset by increased interest due to additional debt of the combined company and an increase in restructuring and severance related payments.

#### Cash Flows from Investing Activities

The decrease in cash used in investing activities of $387 million for the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018, was primarily related to a decrease in cash paid for acquisitions, an increase in proceeds from corporate owned life insurance and an increase in the proceeds received on the sale of international businesses.

#### Cash Flows from Financing Activities

Net cash used in financing activities was $39 million for the nine months ended September 30, 2019 compared to net cash provided by financing activities of $507 million for the nine months September 30, 2018. The change was primarily attributable to a decrease in net proceeds from our Term Loan and an increase in tax distributions to non-controlling interests partially offset by a decrease in distributions to members.

### UK Divestiture

On March 30, 2019, Amneal sold 100% of the stock of its Creo Pharma Holding Limited subsidiary, which comprised substantially all of our operations in the United Kingdom, to AI Sirona (Luxembourg) Acquisition S.a.r.l for net cash consideration of approximately $32 million which was received in April 2019.

### Germany Divestiture

On May 3, 2019, the Company sold 100% of the stock of its Amneal Deutschland GmbH subsidiary, which compromised substantially all of our operations in Germany, to EVER Pharma Holding Ges.m.b.H. for net cash consideration of approximately $3 million which was received in May 2019.

### Commitments and Contractual Obligations

The contractual obligations of the Company are set forth in *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* contained in the Company’s 2018 Annual Report on Form 10-K. We include herein certain updates to those obligations. The $50 million Levothyroxine license and supply contract liability outstanding at March 31, 2019 was paid in April 2019.

### Levothyroxine License and Supply Agreement; Transition Agreement

On August 16, 2018, the Company entered into a license and supply agreement with Jerome Stevens Pharmaceuticals, Inc. ("JSP") for Levothyroxine. This agreement designated the Company as JSP's exclusive commercial partner for Levothyroxine in the U.S. market for a 10-year term commencing on March 22, 2019. Under this license and supply agreement with JSP, the Company accrued the up-front license payment of $50 million on March 22, 2019, which was paid in April 2019. The agreement also provides for the Company to pay a profit share to JSP based on net profits of the Company's sales of Levothyroxine, after considering product costs.

On November 9, 201 8, the Company entered into a transition agreement ("Transition Agreement") with Lannett and JSP. Under the terms of the Transition Agreement, the Company assumed the distribution and marketing of Levothyroxine from Lannett beginning December 1, 2018 through March 22, 2019, ahead of the commencement date of the license and supply agreement with JSP described above.

In accordance with the terms of the Transition Agreement, the Company made $47 million of non-refundable payments to Lannett. For the nine months ended September 30, 2019 and the year ended December 31, 2018, $37 million and $ 10 million, respectively, were expensed to cost of goods sold, as the Company sold Levothyroxine. As of December 31, 2018, the Company had a $4 million transition contract liability, which was fully settled in February 2019.

### Outstanding Debt Obligations

### Term Loan and Revolving Credit Agreements

On May 4, 2018 we entered into a senior credit agreement that provided the Term Loan with a principal amount of $2.7 billion and the ABL under which loans and letters of credit up to a principal amount of $500 million are available (principal amount of up to $25 million is available for letters of credit) (collectively, the "Senior Secured Credit Facilities"). The Term Loan is repayable in equal quarterly installments at a rate of 1.00% or the original principal amount annually, with the balance payable at maturity on May 4, 2025. The Term Loan bears a variable annual interest rate, which is one-month LIBOR plus 3.5% at September 30, 2019. The ABL bears an annual interest rate of one-month LIBOR plus 1.5% at September 30, 2019 and matures on May 4, 2023. As of September 30, 2019, the annual interest rate for the ABL may be reduced or increased by 0.25% based on step-downs and step-ups determined by the average historical excess availability. At September 30, 2019, we had no outstanding borrowings under the ABL.

The proceeds of any loans made under the Senior Secured Credit Facility can be used for capital expenditures, acquisitions, working capital needs and other general purposes, subject to covenants as described below. We pay a commitment fee based on the average daily unused amount of the ABL at a rate based on average historical excess availability, between 0.25% and 0.375% per annum. At September 30, 2019, the ABL commitment fee rate is 0.375% per annum.

The Senior Secured Credit Facilities contain a number of covenants that, among other things, create liens on Amneal's and its subsidiaries' assets. The Senior Secured Credit Facilities contain certain negative covenants that, among other things and subject to certain exceptions, restrict Amneal’s and its subsidiaries' ability to incur additional debt or guarantees, grant liens, make loans, acquisitions or other investments, dispose of assets, merge, dissolve, liquidate or consolidate, pay dividends or other payments on capital stock, make optional payments or modify certain debt instruments, modify certain organizational documents, enter into arrangements that restrict the ability to pay dividends or grant liens, or enter into or consummate transactions with affiliates. The ABL also includes a financial covenant whereby Amneal must maintain a minimum fixed charge coverage ratio if certain borrowing conditions are met. The Senior Secured Credit Facilities contain customary events of default, subject to certain exceptions. Upon the occurrence of certain events of default, the obligations under the Senior Secured Credit Facilities may be accelerated and the commitments may be terminated. At September 30, 2019, Amneal was in compliance with all covenants under the Senior Secured Credit Facilities.

### Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2019.

### Critical Accounting Policies

For a discussion of the Company’s critical accounting policies, see *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* in our 2018 Annual Report on Form 10-K. Other than as set forth below, there have been no material changes to the disclosure presented in our 2018 Annual Report on Form 10-K.

### Impairment of Goodwill

In January 2017, the Financial Accounting Standards Board issued ASU 2017-04, *Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment* that eliminates the requirement to calculate the implied fair value of goodwill (i.e., Step 2 of today’s goodwill impairment test) to measure a goodwill impairment charge. We adopted ASU 2017-04 as of April 1, 2019 on a prospective basis and have updated our critical accounting policy accordingly.

Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. We review goodwill for possible impairment annually during the fourth quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable.

In order to test goodwill for impairment, an entity is permitted to first assess qualitative factors to determine whether a quantitative assessment of goodwill is necessary. The qualitative factors considered by us may include, but are not limited to, general economic conditions, our outlook, market performance of our industry and recent and forecasted financial performance. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. If a quantitative assessment is required, we determine the fair value of the reporting unit using a discounted cash flow analysis. If the net book value of the reporting unit exceeds its fair value, we recognize a goodwill impairment charge for the reporting unit equal to the lesser of (i) the total goodwill allocated to that reporting unit and (ii) the amount by which that reporting unit’s carrying amount exceeds its fair value.

Goodwill is allocated and evaluated for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment. We have two reportable segments, Generics and Specialty, which are the same as the respective operating segments and reporting units. As of September 30, 2019, $361 million and $59 million of goodwill was allocated to our Specialty and Generics segments, respectively.

#### Interim Goodwill Impairment Test

In light of the decline in our share price and financial performance, we performed an interim goodwill impairment test during the three months ended September 30, 2019 by evaluating our two reporting units, which are the same as our two reportable segments. The fair values of each of our reporting units were determined by combining both the income and market approaches. In performing this test, the Company utilized long-term growth rates for its reporting units ranging from no growth to 1.0% and discount rates ranging from 9.0% to 11.5% in its estimation of fair value. The assumptions used in evaluating goodwill for impairment are subject to change and are tracked against historical performance by management.

Based on the results of the interim test performed as of August 31, 2019 and updated on September 30, 2019, we determined that the estimated fair values of the Generics and Specialty reporting units exceeded their respective carrying amounts; therefore, the Company did not record a goodwill impairment charge for the three months ended September 30, 2019. The Generics reporting unit was in excess of its carrying value by approximately 15% and the Specialty reporting unit was in excess of its carrying value by approximately 9%.

A 50-basis point increase in the assumed discount rates utilized in each test would have not created a goodwill impairment charge in our Generics reporting unit or our Specialty reporting unit.

Significant judgment is employed in determining the assumptions utilized as of the acquisition date and for each subsequent measurement period. Accordingly, changes in assumptions described above, could have a material impact on our consolidated results of operations.

For each of our reporting units, there are a number of future events and factors that may impact future results and the outcome of subsequent goodwill impairment testing. For a list of these factors, see *Item 1A. Risk Factors.*

### Recently Issued Accounting Standards

Recently issued accounting standards are discussed in *Note 2. Summary of Significant Accounting Policies.*

## Market risk

As filed, 210 characters.

For a discussion of the Company’s quantitative and qualitative disclosures about market risks, see *Item 7A. Quantitative and Qualitative Disclosures About Market Risk* , in our 2018 Annual Report on Form 10-K.

## Controls and procedures

As filed, 3,437 characters.

### Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act, were effective as of September 30, 2019 at the reasonable assurance level.

### Changes in Internal Control over Financial Reporting

During the quarter ended September 30, 2019, there were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) which materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

### Limitations on the Effectiveness of Controls

Systems of disclosure controls and internal controls over financial reporting and their associated policies and procedures, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the system of control are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of internal control, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide a reasonable assurance of achieving their objectives. We conduct periodic evaluations of our systems of controls to enhance, where necessary, our control policies and procedures.

## Risk factors

As filed, 9,986 characters.

Other than as set forth below, there have been no material changes to the disclosure presented in our 2018 Annual Report on Form 10-K under *Item 1A. Risk Factors.*

***We are controlled by the Amneal Group. The interests of the Amneal Group may differ from the interests of our other stockholders.***

As of September 30, 2019, the group of shareholders who owned Amneal prior to the Combination (the "Amneal Group") controlled approximately 55% of the voting power of all of our outstanding shares of common stock.

Through its control of a majority of our voting power and the provisions set forth in our charter, bylaws and the Second Amended and Restated Stockholders Agreement dated December 16, 2017 (the "Stockholders Agreement"), the Amneal Group has the ability to designate and elect and has designated and elected a majority of our board of directors. The Amneal Group has control over all matters submitted to our stockholders for approval, including changes in capital structure, transactions requiring stockholder approval under Delaware law and corporate governance, subject to the terms of the Stockholders Agreement relating to the Amneal Group's agreement to vote in favor of directors not designated by the Amneal Group and such other matters that are set forth in the Stockholders Agreement. The Amneal Group may have different interests than our other stockholders and may make decisions adverse such interests.

Among other things, the Amneal Group's control could delay, defer, or prevent a sale of the Company that the Company’s other stockholders support, or, conversely, this control could result in the consummation of such a transaction that our other stockholders do not support. This concentrated control could discourage a potential investor from seeking to acquire Class A Common Stock and, as a result, might harm the market price of that Class A Common Stock.

The Amneal Group could transfer control of us to a third party by transferring its shares. In addition, the Company believes members of the Amneal Group have pledged Amneal Common Units and the corresponding shares of Class B Common Stock to secure borrowings, and other members of the Amneal Group could enter into similar arrangements. In connection with these arrangements, the Company has entered into agreements with certain Amneal Group members and the lending institutions to whom their securities may be pledged. Because of the recent drop in our stock price, the value of pledged Amneal securities has decreased, which could increase the likelihood of a margin call on a pledge of Amneal securities. The voluntary or forced sale of some or all these units or shares pursuant to a margin call or otherwise could cause our stock price to decline and negatively impact our business. Similarly, a voluntary or forced sale could cause the Company to lose its “controlled company” status under the New York Stock Exchange listing requirements, which would require us to comply over a transition period with certain corporate governance requirements from which we are currently exempt, including having a fully independent compensation committee. If all of the Amneal Common Units and corresponding shares of Class B stock were pledged to secure borrowings, a complete foreclosure could result in a change of control.

***Our future success depends on our ability to attract and retain talented employees and consultants.***

Our future success depends, to a substantial degree, upon the continued service of the members of our management team. The loss of the services of members of our management team, or their inability to perform services on our behalf, could have a material adverse effect on our business, condition (financial and otherwise), prospects and results of operations. On August 5, 2019, we announced that President and Chief Executive Officer Robert A. Stewart was leaving the Company and resigning as a director, effective immediately, and would be replaced by Amneal’s co-founders Chirag Patel, who will serve as President and Co-Chief Executive Officer, and Chintu Patel, who will serve as Co-Chief Executive Officer. Each of Chirag Patel and Chintu Patel is a member of the Amneal Group. In connection with this transition, among other changes to the Company's board of directors, Executive Chairman Paul M. Bisaro also resigned from the Company and the board and was replaced on the board by Paul Meister, who will serve as non-executive Chairman of the Board. Any change in senior management involves significant inherent risk, and any failure to effect a smooth transition process could hinder our strategic planning, execution and future performance. While we endeavor to minimize any negative impact associated with changes such as these, there may be uncertainty among investors, employees and others regarding our future direction and performance. Any disruption in our operations, uncertainty regarding our future or negative public perception regarding the change could have a material adverse effect on our business, financial condition, operating results and cash flows.

Our success also depends, to a large extent, upon the contributions of our sales, marketing, scientific and quality assurance staff. We compete with brand and generic pharmaceutical manufacturers for qualified personnel, and our competitors may offer more favorable employment opportunities than we do. If we are not able to attract and retain the necessary personnel to accomplish our business objectives we could experience constraints that would adversely affect our ability to sell and market our products effectively, to meet the demands of our strategic partners in a timely fashion, and to support our research and development programs. In particular, our sales and marketing efforts depend on the ability to attract and retain skilled and experienced sales, marketing and quality assurance representatives. Although we believe that we have been successful in attracting and retaining skilled personnel in all areas of our business, we cannot provide assurance that we can continue to attract, train and retain such personnel. Any failure in this regard could limit the rates at which we generate sales and develop or acquire new products.

***If we determine that our goodwill has become impaired, we may record significant impairment charges, which would adversely affect our financial condition and results of operations.***

Goodwill represents a significant portion of our assets. Goodwill is the excess of cost over the fair market value of net assets acquired in business combinations. In the future, goodwill may increase as a result of future acquisitions. We review our goodwill and indefinite lived intangible assets at least annually for impairment. Impairment may result from, among other things, deterioration in the performance of acquired businesses, adverse market conditions and adverse changes in applicable laws or regulations, including changes that restrict the activities of an acquired business.

Generic pharmaceuticals have faced regular and increasing price erosion each year, placing even greater importance on our ability to continually introduce new products. If these trends continue or worsen, or if we experience further difficulty in this market or the Specialty market, this may continue to adversely affect our revenues and profits in our Generics and Specialty segments. Furthermore, during the first three quarters of 2019, the Company's market capitalization decreased significantly. Additional decline in our market capitalization, even if due to macroeconomic or industry-wide factors, could put pressure on the carrying value of our goodwill in both our Generics and Specialty segments and cause the Company to conduct an interim impairment test. A determination that all or a portion of our goodwill is impaired, although a non-cash charge against earnings, could have a material adverse effect on our results of operations and financial condition.

***If we determine in the future that we will not be able to fully utilize all or part of our deferred tax assets, we would record a valuation allowance through earnings in the period the determination was made, which could have an adverse effect on our results of operations and earnings.***

We record valuation allowances against our DTAs when it is more likely than not that all or a portion of a DTA will not be realized. We routinely evaluate the realizability of our DTAs by assessing the likelihood that our deferred tax assets will be recovered based on all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, estimates of future taxable income, tax planning strategies and results of operations. Estimating future taxable income is inherently uncertain and requires judgment. In projecting future taxable income, we consider our historical results and incorporate certain assumptions, including projected new product launches, revenue growth, and operating margins, among others.

In assessing the need for a valuation allowance in the third quarter of fiscal 2019, we considered all available objective and verifiable evidence both positive and negative, including historical levels of pre-tax income (loss) both on a consolidated basis and tax reporting entity basis, legislative developments, expectations and risks associated with estimates of future pre-tax income, and prudent and feasible tax planning strategies. We currently estimate that as of September 30, 2019 we will have generated a cumulative consolidated three-year pre-tax loss. As a result of this analysis, we considered it more likely than not that we will not realize the benefits of our gross DTAs and therefore, for the three and nine months ended September 30, 2019, we have recorded a valuation allowance of $372 million to reduce the carrying value of these gross DTAs, net of the impact of the reversal of taxable temporary differences, to zero.

Filed Nov 7, 2019.
Source: SEC EDGAR, the filing index for accession 0001564590-19-041240. Last ingested by Listed: Nov 10, 2026, 02:45 ET. No prices; not investment advice.
